Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 170.33 Million EUR | -14.69% |
| 2022 | 199.66 Million EUR | 30.44% |
| 2021 | 153.07 Million EUR | 150.71% |
| 2020 | 61.05 Million EUR | 55.47% |
| 2019 | 39.27 Million EUR | 119.46% |
| 2018 | 17.89 Million EUR | 3.79% |
| 2017 | 17.24 Million EUR | -33.91% |
| 2016 | 26.08 Million EUR | 31.7% |
| 2015 | 19.8 Million EUR | -17.86% |
| 2014 | 24.11 Million EUR | 4.75% |
| 2013 | 23.02 Million EUR | 17.98% |
| 2012 | 19.51 Million EUR | 7.65% |
| 2011 | 18.12 Million EUR | -26.26% |
| 2010 | 24.58 Million EUR | 22.05% |
| 2009 | 20.14 Million EUR | -1.83% |
| 2008 | 20.51 Million EUR | 37.16% |
| 2007 | 14.95 Million EUR | 195.55% |
| 2006 | 5.06 Million EUR | -100.0% |
| 2005 | 912.13 Billion EUR | 57532.56% |
| 2004 | 1.58 Billion EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 29.38 Million EUR | 96.4% |
| 2024 Q1 | 14.96 Million EUR | -70.95% |
| 2023 Q4 | 51.5 Million EUR | -1.29% |
| 2023 Q2 | 19.18 Million EUR | -59.57% |
| 2023 FY | 170.33 Million EUR | -14.69% |
| 2023 Q3 | 52.18 Million EUR | 171.96% |
| 2023 Q1 | 47.45 Million EUR | -39.28% |
| 2022 Q4 | 78.16 Million EUR | 91.19% |
| 2022 Q1 | 53.04 Million EUR | -2.02% |
| 2022 FY | 199.66 Million EUR | 30.44% |
| 2022 Q3 | 40.88 Million EUR | 48.28% |
| 2022 Q2 | 27.57 Million EUR | -48.02% |
| 2021 Q4 | 54.13 Million EUR | 12.99% |
| 2021 Q1 | 23.83 Million EUR | 67.5% |
| 2021 Q2 | 27.18 Million EUR | 14.04% |
| 2021 Q3 | 47.91 Million EUR | 76.26% |
| 2021 FY | 153.07 Million EUR | 150.71% |
| 2020 FY | 61.05 Million EUR | 55.47% |
| 2020 Q1 | 13.91 Million EUR | 62.02% |
| 2020 Q4 | 14.23 Million EUR | -17.41% |
| 2020 Q2 | 15.67 Million EUR | 12.61% |
| 2020 Q3 | 17.23 Million EUR | 9.94% |
| 2019 Q1 | 6.89 Million EUR | 207.35% |
| 2019 Q2 | 9.26 Million EUR | 34.32% |
| 2019 FY | 39.27 Million EUR | 119.46% |
| 2019 Q4 | 8.59 Million EUR | -40.84% |
| 2019 Q3 | 14.52 Million EUR | 56.75% |
| 2018 Q4 | 2.24 Million EUR | -72.3% |
| 2018 FY | 17.89 Million EUR | 3.79% |
| 2018 Q3 | 8.1 Million EUR | 1037.78% |
| 2018 Q2 | 712 Thousand EUR | -89.59% |
| 2018 Q1 | 6.83 Million EUR | 2994.12% |
| 2017 Q2 | 9.38 Million EUR | 47.21% |
| 2017 Q1 | 6.37 Million EUR | 39.35% |
| 2017 FY | 17.24 Million EUR | -33.91% |
| 2017 Q4 | 221 Thousand EUR | -82.5% |
| 2017 Q3 | 1.26 Million EUR | -86.54% |
| 2016 Q3 | 3.51 Million EUR | -59.16% |
| 2016 Q2 | 8.59 Million EUR | -8.59% |
| 2016 FY | 26.08 Million EUR | 31.7% |
| 2016 Q4 | 4.57 Million EUR | 30.28% |
| 2016 Q1 | 9.4 Million EUR | 185.12% |
| 2015 Q3 | 2.94 Million EUR | -58.7% |
| 2015 Q1 | 6.45 Million EUR | 51.68% |
| 2015 FY | 19.8 Million EUR | -17.86% |
| 2015 Q4 | 3.29 Million EUR | 12.21% |
| 2015 Q2 | 7.11 Million EUR | 10.35% |
| 2014 Q1 | 5.93 Million EUR | 36.45% |
| 2014 FY | 24.11 Million EUR | 4.75% |
| 2014 Q3 | 4.9 Million EUR | -45.62% |
| 2014 Q4 | 4.25 Million EUR | -13.35% |
| 2014 Q2 | 9.02 Million EUR | 52.19% |
| 2013 Q2 | 8.49 Million EUR | 59.09% |
| 2013 Q3 | 4.84 Million EUR | -42.93% |
| 2013 Q4 | 4.34 Million EUR | -10.32% |
| 2013 FY | 23.02 Million EUR | 17.98% |
| 2013 Q1 | 5.33 Million EUR | -18.57% |
| 2012 Q2 | 7.7 Million EUR | 46.51% |
| 2012 FY | 19.51 Million EUR | 7.65% |
| 2012 Q3 | 3.67 Million EUR | -52.31% |
| 2012 Q4 | 6.55 Million EUR | 78.46% |
| 2012 Q1 | 5.25 Million EUR | 0.08% |
| 2011 Q2 | 8.02 Million EUR | 65.33% |
| 2011 Q3 | 2.87 Million EUR | -64.16% |
| 2011 FY | 18.12 Million EUR | -26.26% |
| 2011 Q4 | 5.25 Million EUR | 82.71% |
| 2011 Q1 | 4.85 Million EUR | 7341.79% |
| 2010 Q4 | -67 Thousand EUR | -101.17% |
| 2010 Q1 | 4.99 Million EUR | 0.0% |
| 2010 Q2 | 13.93 Million EUR | 179.03% |
| 2010 FY | 24.58 Million EUR | 22.05% |
| 2010 Q3 | 5.72 Million EUR | -58.95% |
| 2009 FY | 20.14 Million EUR | -1.83% |
| 2008 FY | 20.51 Million EUR | 37.16% |
| 2007 FY | 14.95 Million EUR | 195.55% |
| 2006 FY | 5.06 Million EUR | -100.0% |
| 2005 FY | 912.13 Billion EUR | 57532.56% |
| 2004 FY | 1.58 Billion EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | 4560.199% |
| Skye Bioscience, Inc. | -37.64 Million USD | 552.48% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -161.519% |
| Nascent Biotech, Inc. | -2.08 Million USD | 8259.049% |
| Qrons Inc. | -789.34 Thousand USD | 21679.229% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 2107.961% |
| CSL Limited | 2.64 Billion USD | 93.553% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -221.514% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 2539.338% |
| Regen BioPharma, Inc. | 1.02 Million USD | -16542.273% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 372.105% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 41097.259% |
| Rebus Holdings, Inc. | -1.02 Million USD | 16799.51% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 12855.058% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 27034.395% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 1173.217% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 327.225% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 2690.209% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 62402.031% |
| SQZ Biotechnologies Company | -79.46 Million USD | 314.355% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 5989.066% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 9456.352% |
| Mesoblast Limited | -87.95 Million USD | 293.659% |
| Marizyme, Inc. | -65.34 Million USD | 360.663% |
| Genus plc | 7.9 Million USD | -2056.139% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 1663.891% |
| Pharming Group N.V. | -10.54 Million USD | 1714.856% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 7950.212% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 4690.95% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 2025.995% |
| ContraFect Corporation | -65.15 Million USD | 361.438% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 3586.14% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 9960.459% |
| IMV Inc. | -36.48 Million USD | 566.854% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 2213.421% |
| MultiCell Technologies, Inc. | -380.07 USD | 44816844.284% |
| ONE Bio Corp. | 8.67 Million USD | -1863.151% |
| Accustem Sciences Inc. | -3.74 Million USD | 4646.608% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 429.519% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 13542.54% |
| Q BioMed Inc. | -2.05 Million USD | 8400.55% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 4662.952% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 7254.318% |
| Biomind Labs Inc. | -1.21 Million USD | 14127.204% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 385.197% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 5591.545% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 2255.295% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 8838.494% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 1137486.485% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 3028.1% |
| GB Sciences, Inc. | -1.36 Million USD | 12609.207% |
| Alpha Cognition Inc. | -13.77 Million USD | 1336.77% |
| HST Global, Inc. | -146.21 Thousand USD | 116600.239% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 9806.965% |
| Halberd Corporation | -79.67 Thousand USD | 213884.578% |
| Enzolytics Inc. | -2.17 Million USD | 7924.903% |
| Agentix Corp. | -1.37 Million USD | 12495.113% |
| Resverlogix Corp. | -3.61 Million USD | 4818.421% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 5470.911% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 157.73% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -173711.224% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -2359.855% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 4387.322% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 5728.797% |
| AVAX Technologies, Inc. | -6.41 Million USD | 2755.821% |
| Zenith Capital Corp. | -10.59 Million USD | 1707.541% |
| Genscript Biotech Corporation | -95.47 Million USD | 278.404% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 732975.828% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 4208.481% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 281922.106% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 8595.024% |
| Kadimastem Ltd | -3.3 Million USD | 5250.121% |
| Helix BioMedix, Inc. | -1.05 Million USD | 16229.338% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 38692.425% |
| LadRx Corporation | 400.44 Thousand USD | -42436.641% |
| Cell Source, Inc. | -5.32 Million USD | 3301.056% |
| Regen BioPharma, Inc. | 1.02 Million USD | -16542.273% |
| NovAccess Global Inc. | -4.76 Million USD | 3671.573% |
| Affymax, Inc. | -14.42 Million USD | 1280.914% |
| Itoco Inc. | -1.86 Million USD | 9213.722% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 3934.185% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 10305.812% |
| Mobile Lads Corp. | -2.26 Million USD | 7625.984% |
| CytoDyn Inc. | -49.84 Million USD | 441.757% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 215623.895% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 74766.743% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 18191.317% |
| SYBLEU INC | -180.3 Thousand USD | 94571.005% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 10661.859% |
| International Stem Cell Corporation | -131 Thousand USD | 130126.718% |
| Bioxytran, Inc. | -4.28 Million USD | 4079.788% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 313954.29% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 6831.951% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 454.333% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 8157.474% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 21913.015% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 5476.736% |
| Neutra Corp. | -233.46 Thousand USD | 73059.544% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 939.461% |
| PureTech Health plc | -65.69 Million USD | 359.274% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 900.953% |
| IXICO plc | -1.17 Million USD | 14559.677% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 1815.876% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 398.164% |
| CSL Limited | 2.64 Billion USD | 93.553% |
| Cellectis S.A. | -103.17 Million USD | 265.095% |